Vcanbio Cell & Gene Engineering Second Quarter 2024 Earnings: EPS: CN¥0.09 (vs CN¥0.10 in 2Q 2023)

Simply Wall St · 08/31 01:04

Vcanbio Cell & Gene Engineering (SHSE:600645) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥404.3m (down 3.8% from 2Q 2023).
  • Net income: CN¥45.0m (flat on 2Q 2023).
  • Profit margin: 11% (in line with 2Q 2023).
  • EPS: CN¥0.09 (down from CN¥0.10 in 2Q 2023).
earnings-and-revenue-history
SHSE:600645 Earnings and Revenue History August 31st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Vcanbio Cell & Gene Engineering shares are up 3.7% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Vcanbio Cell & Gene Engineering's balance sheet and an in-depth analysis of the company's financial position.